GlassScriptPhysician profile
Shnehal C Patel
NPI 1972820447
$198,173.74
in general payments reported to CMS, 2019-2025
16 companies · $58K in 2025
The $58K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $8,636 · 2021: $30K · 2022: $47K · 2023: $17K · 2024: $12K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Travel and Lodging: $13K · Honoraria: $9,047 · Food and Beverage: $2,645 · Consulting Fee: $1,500 · Education: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,418.39 |
| Travel and Lodging | $13,298.72 |
| Honoraria | $9,046.88 |
| Food and Beverage | $2,644.67 |
| Consulting Fee | $1,500.00 |
| Education | $1,299.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126,691.80 | 2019-2025 | |
| Mdd US Operations, LLC | $22,386.29 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Kyowa Kirin, INC. | $15,127.17 | 2022-2023 | Nourianz |
| Amneal Pharmaceuticals LLC | $10,323.50 | 2024-2025 | Ongentys, Crexont |
| Adamas Pharmaceuticals, INC. | $7,680.00 | 2021 | |
| Neurocrine Biosciences, INC. | $5,759.92 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $5,547.05 | 2022 | |
| Medtronic, INC. | $1,635.01 | 2022 | |
| Abbott Laboratories | $1,507.26 | 2022-2023 | Infinity |
| Boston Scientific Corporation | $840.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $273.28 | 2020-2025 | Austedo Xr |
| Allergan, INC. | $203.16 | 2021 | |
| Acorda Therapeutics, INC | $88.09 | 2019 | |
| Insightec,INC | $84.28 | 2021 | |
| Baxter Healthcare | $13.93 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shnehal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.